Joslin researchers find key mechanism in increased atherosclerosis risk for people with diabetes

July 10, 2013

Boston - July 10, 2013 - Researchers at Joslin Diabetes Center have discovered that when excessive PKC beta is found in the endothelium, the thin layer of cells that line blood vessels, atherosclerosis is exacerbated. Their findings were published on-line on June 11 by Circulation Research.

For people with diabetes, the increased risk of cardiovascular disease is an unfortunate reality. This includes atherosclerosis, a condition where the walls of the artery thicken due to accumulating fatty deposits, which can lead to heart attack and stroke.

"Heart disease is a major cause of death for both type 1 and type 2 [diabetes]," says George King, M.D., Chief Scientific Officer and Director of Research at Joslin. A team of researchers at Joslin led by Dr. King is one step closer to finding a solution for this insidious problem.

It is known that diabetic episodes of hyperglycemia and elevated levels of fatty acids cause the body to produce excessive amounts of PKC beta, an enzyme that plays a number of biological roles and has been shown to affect the cardiovascular system.

To study the link between PKC beta and atherosclerosis, scientists compared two groups of mice that were bred without the ability to produce apoliprotein E, a lipoprotein that removes cholesterol and lipids from the blood stream, giving them an innate tendency to develop atherosclerosis. One of these two groups was also bred to produce excessive levels of PKC beta in the endothelium. Both groups were fed a high fat, Western diet for twelve weeks after which researchers assessed their cardiovascular health.

The mice all gained weight at the same rate and had comparable blood pressures, cholesterol, and triglyceride rates. However, the group of mice that had elevated PKC beta experienced drastically higher rates of atherosclerosis. Joslin researchers learned that PKC beta inhibits the body's natural anti-atherogenic responses, which normally prevent fatty deposits from building up in blood vessels. As a result, the amount of aortic plaque in the PKC beta mice was twice that of control mice and their aortic atherosclerotic lesions were 1.7 times larger. Their endothelial walls also displayed signs of increased infection and inflammation.

Researchers believe that this greater instance of cardiovascular disease occurs partly because PKC beta indirectly inhibits the production of the anti-atherogenic, nitric oxide. Nitric oxide is vital to cardiovascular health, reducing the work the heart has to perform to pump blood and lowering the heart rate. In fact, lowered levels of nitric oxide are an early indicator of cardiovascular disease.

Now that excessive PKC beta has been shown to exacerbate atherosclerosis, researchers are hopeful that they will find better ways to manage cardiovascular disease in diabetic patients.

"If we could come up with a treatment for decreasing PKC beta, it may decrease the risk of cardiovascular disease in both Type 1 and Type 2 diabetes," says Dr. King.
-end-
About Joslin Diabetes Center

Joslin Diabetes Center, located in Boston, Massachusetts, is the world's largest diabetes research and clinical care organization. Joslin is dedicated to ensuring that people with diabetes live long, healthy lives and offers real hope and progress toward diabetes prevention and a cure. Joslin is an independent, nonprofit institution affiliated with Harvard Medical School.

Our mission is to prevent, treat and cure diabetes. Our vision is a world free of diabetes and its complications. For more information, visit http://www.joslin.org.

About Joslin Research

Joslin Research comprises the most comprehensive and productive effort in diabetes research under one roof anywhere in the world. With 30-plus faculty-level investigators and an annual research budget of $36 million, Joslin researchers focus on unraveling the biological, biochemical and genetic processes that underlie the development of type 1 and type 2 diabetes and related complications.

Joslin research is highly innovative and imaginative, employing the newest tools in genetics, genomics and proteomics to identify abnormalities that may play a role in the development of diabetes and its complications. Joslin Clinic patients, and others with diabetes, have the option of participating in clinical trials at Joslin to help translate basic research into treatment innovations.

Joslin has one of the largest diabetes training programs in the world, educating 150 M.D. and Ph.D. researchers each year, many of whom go on to head diabetes initiatives at leading institutions all over the globe. For more information, visit http://www.joslinresearch.org.

Joslin Diabetes Center

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.